Navigation Links
AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
Date:6/29/2009

    GAI-122, an investigational injectable nanoemulsion formulated with
    AlphaRx's proprietary drug delivery technology, providing significant
    neuro-protection in multiple in vitro and in vivo studies which suggest
    that this injectable nanoemulsion formulation has the potential to
    prevent postoperative delirium

MARKHAM, ON, June 29 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX) and Gaia BioPharma Limited today reported positive pre-clinical results on GAI-122 injectable nanoemulsion in multiple in vitro and in vivo studies of memory impairment after prolonged anesthesia.

Delirium is a common mental disorder with serious adverse outcomes in post-operative hospitalized patients. It is associated with an increase in mortality, physical morbidity, length of hospital stay, institutionalization of patients and increased cost to healthcare providers. Ten to thirty percent of admissions of patients over 65 years of age to a general hospitals develop delirium after surgery and the incidence rate can be as high as 50% in patients who undergone high risk and lengthy procedures such as hip replacement and cardiac surgeries. There is no preventive therapy currently available for post-operative delirium.

"There are over 10,000,000 inpatient surgeries performed annually in the U.S. on patients over the age of 65, and up to 40% of these seniors will develop post-operative delirium. There is an urgent need to develop a medicine, such as GAI-122 injectable nanoemulsion, for the preventive of this debilitating post-operative condition," said Dr. Michael Weisspapir, MD, PhD, Chief Medical Scientist of AlphaRx.

In rat model studies, injected GAI-122 ameliorates learning and memory disturbances produced by cerebral embolization, cerebral ischemia or lesions in the basal forebrain, the area of origin of the acetylcholine neuron system projecting into the cerebral cortex, hippocampus and amygdala. In clinical tests, an oral form of GAI-122 has been shown to be effective in psychological deficits such as a decline in memory retention and disorientation.

In October 2008, AlphaRx licensed GAI-122 to Gaia BioPharma. Under the terms of the amended agreement, AlphaRx is eligible to receive milestone payments of up to $50 million for the successful development and commercialization of GAI-122, as well as royalties on worldwide sales. In addition, Gaia BioPharma has assumed all development costs.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

About Gaia BioPharma

Gaia BioPharma Limited, a privately held, early stage biopharmaceutical company focused on hospital-based injectable therapeutics. Gaia BioPharma seeks to address key unmet therapeutic needs by taking established compounds and changing their administration routes to create patent-protected, value-added products.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx Shareholder Update
2. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
3. AlphaRx Signs Cooperative Research and Development Agreement with US Army
4. AlphaRx Provides Corporate and Development Update
5. AlphaRxs Indaflex(TM) Continues its Clinical Development
6. AlphaRx CEO Accumulates More Company Shares
7. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
8. AlphaRx Announces Debt Conversion
9. AlphaRx To Present at 47th Annual ICAAC
10. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
11. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
Breaking Medicine Technology: